| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Renin-angiotensin-aldosterone system (RAAS); angiotensin II (Ang II) signaling. Prosaikogenin G inhibits angiotensin II (Ang II)-induced rat mesangial cell proliferation. Ang II is a key mediator of the renin-angiotensin-aldosterone system (RAAS) involved in renal function and blood pressure regulation. By inhibiting Ang II-induced mesangial cell proliferation, the compound exerts protective effects on the kidney. Its anti-inflammatory and hepatoprotective activities suggest modulation of inflammatory cytokine and oxidative stress pathways.
|
|---|---|
| ln Vitro |
Prosaikogenin G (25, 50 μM) does not harm normal MC and protects the kidney from the down-regulated activity that Ang II (1 μM) induces in the rat mesangial cell line (MC) proliferation[1].
Prosaikogenin G (25, 50 μM) does not harm normal rat mesangial cells (MC) and protects the kidney from the down-regulated activity that Ang II (1 μM) induces in rat mesangial cell proliferation. The compound shows significant inhibitory effects on Ang II-induced mesangial cell proliferation. It exhibits notable anti-inflammatory and hepatoprotective activities. The compound’s protective effects on the kidney suggest potential for managing renal disorders. |
| ln Vivo |
In vivo studies of prosaikogenin G are limited. As a derivative of saikosaponin d formed in the gastrointestinal tract, it is expected to contribute to the pharmacological effects of Bupleurum chinensis, which has been used in traditional medicine for liver and kidney disorders. Its anti-inflammatory and hepatoprotective activities suggest potential benefits in animal models of liver disease, immune dysregulation, and chronic inflammation. Further in vivo studies are needed to characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Non-cell-based assays for prosaikogenin G include enzyme inhibition studies to assess its effects on the renin-angiotensin system. Angiotensin-converting enzyme (ACE) inhibition assays can be performed using purified ACE and a fluorogenic substrate. The compound’s ability to inhibit ACE is measured by fluorescence detection. Anti-inflammatory activity can be assessed by measuring inhibition of cytokine production in enzyme-linked immunosorbent assays (ELISA). Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for prosaikogenin G use rat mesangial cell lines (MC) to assess its protective effects against Ang II-induced proliferation. Cells are treated with Ang II (1 μM) to induce proliferation, and prosaikogenin G (25, 50 μM) is added to assess its inhibitory effects. Cell proliferation is measured using MTT or BrdU incorporation assays. The compound’s effects on inflammatory cytokine production can be assessed in macrophage cell lines. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo studies of prosaikogenin G are limited. Based on its biological activities, potential animal models include: models of renal disease for evaluating nephroprotective effects; models of liver injury for hepatoprotective evaluation; and models of chronic inflammation for anti-inflammatory evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Prosaikogenin G has a molecular formula of C₃₆H₅₈O₈ and a molecular weight of 618.84 g/mol. It is a monodesmosidic oleanane-type triterpenoid saponin isolated from the roots of Bupleurum chinensis DC.. It is a derivative of saikosaponin d formed in the gastrointestinal tract. The compound should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for prosaikogenin G are limited. The compound does not harm normal rat mesangial cells at concentrations of 25-50 μM, suggesting low cytotoxicity to normal cells. As a natural saponin, it is generally considered to have low toxicity. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that Bupleurum contains prosapogenin G, and relevant data is available for reference.
Prosaikogenin G (buipusaponin G) is a monodesmosidic oleanane-type triterpenoid saponin isolated from the roots of Bupleurum chinensis DC.. It is a derivative of saikosaponin d formed in the gastrointestinal tract. The compound inhibits Ang II-induced rat mesangial cell proliferation and has protective effects on the kidney. It also exhibits anti-inflammatory and hepatoprotective activities and is being studied for its potential in managing liver disorders, immune dysregulation, and chronic inflammation. It is for research use only. |
| Molecular Formula |
C36H58O8
|
|---|---|
| Molecular Weight |
618.840932369232
|
| Exact Mass |
618.413
|
| CAS # |
99365-23-8
|
| PubChem CID |
101596925
|
| Appearance |
White to off-white solid
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
44
|
| Complexity |
1190
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@H]([C@]2(C)CO)CC[C@@]4([C@@H]3C=C[C@@]56[C@]4(C[C@H]([C@@]7([C@H]5CC(CC7)(C)C)CO6)O)C)C)C)O)O)O
|
| InChi Key |
WSSVJIGMYVWUJL-PSLKBDIJSA-N
|
| InChi Code |
InChI=1S/C36H58O8/c1-20-26(39)27(40)28(41)29(43-20)44-25-10-11-31(4)21(32(25,5)18-37)8-12-33(6)22(31)9-13-36-23-16-30(2,3)14-15-35(23,19-42-36)24(38)17-34(33,36)7/h9,13,20-29,37-41H,8,10-12,14-19H2,1-7H3/t20-,21-,22-,23-,24-,25+,26+,27+,28-,29+,31+,32+,33-,34+,35-,36+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R,6R)-2-[[(1S,2R,4S,5R,8R,9R,10S,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxane-3,4,5-triol
|
| Synonyms |
Prosaikogenin G
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (80.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6159 mL | 8.0796 mL | 16.1593 mL | |
| 5 mM | 0.3232 mL | 1.6159 mL | 3.2319 mL | |
| 10 mM | 0.1616 mL | 0.8080 mL | 1.6159 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
